Purpose to compare effect Ranibizumab and Aflibercept, for the treatment of macular edema secondary to non-ischemic central retinal vein occlusion CRVO in young adults. Methods Forty eyes of 40 young adult patients with macular edema due to CRVO were enrolled in this prospective double-armed clinical trial. The patients were randomized into 2 groups of 20 patients each. First group received intravitreal injection of Ranibizumab while second group received Aflibercept. All patients were subjected to measurement of Best corrected visual acuity BCVA, fluorescein angiography (FA) to detect retinal ischemia and Spectral domain OCT (SD-OCT) to measure macular edema at baseline and during 12-month follow up period. Intravitreal injections were three injections with a 1-month interval between injections